Tradestie Institutional Equity Comparison Engine

SGMO vs RLMD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RLMD Overall Edge

RLMD Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Relmada Therapeutics, Inc. Common Stock (RLMD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while SGMO counters with relative strength in Valuation. Fundamentally, SGMO trades at 0.4x Forward P/E with -175.5% operating margin (+88.4% YoY revenue) versus RLMD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against RLMD sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
SGMO 0.4x vs RLMD N/M Fwd P/E
Growth & Margin Winner RLMD
Op Margin -175.5% vs 0.0% ยท YoY +88.4% vs +0.0%
Momentum & Technical Winner RLMD
1Y -76.0% vs -6.8% ยท 52W Pos 9% vs 11%
Options & Structure Winner RLMD
UNCLASSIFIED (71st %ile IV) vs BREAKDOWN (36th %ile IV)
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
RLMD NASDAQ
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.62
-14.13% 1D
Market Cap $421.3M
1M Return +16.61%
1Y Return -6.83%
Forward P/E N/M
Unified AI Score
35.3 / 100 SELL
Tech 50.0 Fund 34.0 Flow 71.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGMO -76.04% RLMD -6.83% Spread: +151.44 pp (RLMD Lead)

Pillar 3 Multi-Year Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SGMO Revenue RLMD Revenue SGMO Op. Margin RLMD Op. Margin Margin Edge
FY2012 N/A $0M N/A -151.8% RLMD
FY2013 N/A $0M N/A -877.7% RLMD
Q1 '25 $30M N/A -460.3% N/A SGMO
Q1 '26 $10M N/A -2215.4% N/A SGMO
Q2 '25 $70M N/A -97.5% N/A SGMO
Q3 '25 $0M N/A -6119.3% N/A SGMO
Q4 '25 $60M N/A -175.5% N/A SGMO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGMO (4) vs RLMD (5)
Institutional Metric SGMO RLMD Criterion Row Winner
Market Capitalization Scale $55.9M $421.3M Larger Scale RLMD
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Forward P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY) Growth +88.4% +0.0% Higher Growth SGMO
Operating Margin (TTM) Profitability -175.5% 0.0% Higher Margin RLMD
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2891.8% -64.7% Higher ROE RLMD
52-Week Range Position Momentum 9% ($0โ€“$1) 11% ($3โ€“$8) Stronger Trend RLMD
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 206% Vol 1.61ฮฒ ยท 98% Vol Lower Realized Risk RLMD
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 35.3 / 100 (SELL) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGMO vs RLMD Buy Guide
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RLMD BREAKDOWN
134d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RLMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGMO nor RLMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.